Tekmira Pharmaceuticals (TKMR) disclosed today that it has filed an amended complaint against Alnylam Pharmaceuticals, Inc. (ALNY) with the Business Litigation Session of the Massachusetts Superior Court.
Tekmira’s revised complaint brings new claims alleging violation of contract, breach of the intended covenant of good faith and fair dealing, tortious interference with contractual associations, and civil conspiracy. The amended complaint additionally adds AlCana Technologies as a defendant and asserts claims alleging misappropriation of trade secrets, tortious interference with contractual relations, unfair enrichment, unjust and misleading acts and trade methods, and civil conspiracy against AlCana. Throughout the litigation, Alnylam has stated that, among other claims that Tekmira is in violation of the license and production agreements involving the two companies.
As referred to in the amended complaint, Tekmira is seeking relief in the form of damages – including the royalties and profits Alnylam and AlCana would receive from the alleged improper use of Tekmira’s technology and the termination of Alnylam’s license to Tekmira’s technology.